Crescent Biopharma (CBIO) Competitors $14.24 +0.55 (+4.02%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesOwnershipSEC FilingsSustainabilityTrendsBuy This Stock CBIO vs. OPK, GERN, RIGL, ZBIO, VSTM, MYGN, EBS, LXRX, XOMA, and VNDAShould you be buying Crescent Biopharma stock or one of its competitors? The main competitors of Crescent Biopharma include OPKO Health (OPK), Geron (GERN), Rigel Pharmaceuticals (RIGL), Zenas BioPharma (ZBIO), Verastem (VSTM), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. Crescent Biopharma vs. Its Competitors OPKO Health Geron Rigel Pharmaceuticals Zenas BioPharma Verastem Myriad Genetics Emergent Biosolutions Lexicon Pharmaceuticals XOMA Royalty Vanda Pharmaceuticals OPKO Health (NASDAQ:OPK) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership. Is OPK or CBIO more profitable? Crescent Biopharma has a net margin of 0.00% compared to OPKO Health's net margin of -26.68%. OPKO Health's return on equity of -13.17% beat Crescent Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets OPKO Health-26.68% -13.17% -8.28% Crescent Biopharma N/A -106.06%-86.60% Do institutionals & insiders believe in OPK or CBIO? 64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by company insiders. Comparatively, 4.0% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, OPK or CBIO? OPKO Health has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Do analysts rate OPK or CBIO? OPKO Health presently has a consensus target price of $2.75, indicating a potential upside of 103.70%. Crescent Biopharma has a consensus target price of $25.60, indicating a potential upside of 79.78%. Given OPKO Health's higher probable upside, equities analysts clearly believe OPKO Health is more favorable than Crescent Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OPKO Health 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Crescent Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Which has higher earnings & valuation, OPK or CBIO? Crescent Biopharma has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOPKO Health$713.10M1.50-$53.22M-$0.25-5.40Crescent Biopharma$10K27,839.20-$37.88M-$34.93-0.41 Does the media refer more to OPK or CBIO? In the previous week, OPKO Health had 6 more articles in the media than Crescent Biopharma. MarketBeat recorded 6 mentions for OPKO Health and 0 mentions for Crescent Biopharma. OPKO Health's average media sentiment score of 1.11 beat Crescent Biopharma's score of 0.20 indicating that OPKO Health is being referred to more favorably in the media. Company Overall Sentiment OPKO Health Positive Crescent Biopharma Neutral SummaryCrescent Biopharma beats OPKO Health on 9 of the 17 factors compared between the two stocks. Get Crescent Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBIO vs. The Competition Export to ExcelMetricCrescent BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$278.39M$2.64B$5.77B$9.93BDividend YieldN/A49.35%6.67%4.52%P/E Ratio-0.4123.0375.6026.68Price / Sales27,839.20752.40555.18213.69Price / CashN/A169.7737.1158.92Price / Book1.735.5011.446.09Net Income-$37.88M$32.95M$3.28B$266.14M7 Day Performance-1.11%2.69%0.84%0.27%1 Month Performance22.76%7.87%7.15%4.13%1 Year PerformanceN/A0.79%59.65%23.93% Crescent Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBIOCrescent Biopharma3.5529 of 5 stars$14.24+4.0%$25.60+79.8%N/A$278.39M$10K-0.4150News CoverageHigh Trading VolumeOPKOPKO Health4.3904 of 5 stars$1.40+0.4%$2.75+97.1%-14.8%$1.11B$713.10M-5.582,997Positive NewsGERNGeron3.214 of 5 stars$1.45+1.8%$4.19+189.8%-67.8%$921.94M$76.99M-11.12229Positive NewsRIGLRigel Pharmaceuticals2.7776 of 5 stars$41.04+0.7%$38.20-6.9%+204.5%$737.23M$267.92M7.60160Positive NewsShort Interest ↓ZBIOZenas BioPharma1.6551 of 5 stars$16.81+1.5%$36.67+118.1%N/A$707.87M$5M-4.74N/ATrending NewsAnalyst RevisionGap UpVSTMVerastem2.2314 of 5 stars$8.84-1.5%$13.29+50.2%+332.8%$543.71M$10K-2.6950MYGNMyriad Genetics3.7762 of 5 stars$5.80-1.6%$12.45+114.9%-73.2%$540.10M$837.60M-1.362,700Positive NewsEBSEmergent Biosolutions4.826 of 5 stars$8.59-6.6%$14.33+66.9%+2.9%$459.08M$1.04B3.512,420Positive NewsAnalyst ForecastLXRXLexicon Pharmaceuticals2.1171 of 5 stars$1.14+0.4%$3.23+184.1%-34.4%$412.46M$31.08M-3.44140Analyst ForecastXOMAXOMA Royalty3.857 of 5 stars$33.90+0.4%$69.50+105.0%+24.6%$409.90M$28.49M-21.8710Positive NewsVNDAVanda Pharmaceuticals4.07 of 5 stars$4.66+1.0%$16.50+254.5%-8.7%$275.06M$198.77M-4.12290 Related Companies and Tools Related Companies OPKO Health Competitors Geron Competitors Rigel Pharmaceuticals Competitors Zenas BioPharma Competitors Verastem Competitors Myriad Genetics Competitors Emergent Biosolutions Competitors Lexicon Pharmaceuticals Competitors XOMA Royalty Competitors Vanda Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBIO) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
